Aquestive Therapeutics, Inc.: directors' dealings · United States · SEC (Form 4)

About Aquestive Therapeutics, Inc.

Aquestive Therapeutics, Inc. (NASDAQ: AQST) is a U.S.-listed biopharmaceutical company traded on the NASDAQ market in the United States. Founded in 2005 as MonoSol Rx and later renamed Aquestive Therapeutics, the company has built its identity around PharmFilm®, a proprietary oral and sublingual thin-film drug delivery platform designed to deliver complex molecules without needles or conventional invasive devices. For investors in French-speaking Europe, Aquestive should be viewed less as a broad large-cap pharma company and more as a specialized drug-delivery and formulation platform business with selective proprietary assets. The company’s operating model rests on three pillars. First, it commercializes licensed products and generates revenue from products marketed through partners. Second, it develops proprietary late-stage candidates that may create higher upside if approved and launched successfully. Third, it collaborates with pharmaceutical companies to reformulate established molecules into differentiated dosage forms using its technology. Aquestive has already secured multiple FDA approvals over time, including Zuplenz® (ondansetron), Suboxone® film, Sympazan® and Exservan®, demonstrating both regulatory execution and manufacturing know-how. Its production facilities are located in Portage, Indiana, while its corporate headquarters and primary research laboratories are in Warren, New Jersey. From a competitive standpoint, Aquestive occupies a niche position in oral and sublingual formulations where ease of administration, rapid onset, patient convenience and adherence can matter materially. That positioning gives it differentiation in therapeutic areas such as severe allergies, central nervous system disorders and other specialty indications. However, the company remains relatively small, and its market narrative is driven more by product pipeline milestones than by a broad commercial footprint. The key asset for investors is Anaphylm™, a no-needle, no-device epinephrine sublingual film intended for severe allergic reactions, including anaphylaxis. In 2025, Aquestive disclosed FDA acceptance of the NDA and a PDUFA target action date of January 31, 2026. Following a subsequent regulatory setback announced in 2026, the company said it expects to resubmit the NDA in Q3 2026, assuming completion of the required HF and PK studies. Another important development program is AQST-108, a topical epinephrine prodrug gel being evaluated for alopecia areata and other dermatology opportunities; the company opened an IND with the FDA in late 2025. Geographically, Aquestive remains primarily U.S.-based in terms of operations, manufacturing and headquarters, even though it may leverage licensing and collaboration arrangements beyond the United States. Recent headlines include an August 2025 equity financing to support potential commercialization of Anaphylm, plus continued clinical and regulatory progress across its pipeline. Overall, Aquestive is best characterized as a catalyst-driven specialty pharma name, where valuation is highly sensitive to FDA decisions, clinical data and commercial execution.